These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25219741)

  • 1. Erythrodermic CD8+ pseudolymphoma during infliximab treatment in a patient with psoriasis: use of cyclosporine as a rescue therapy.
    Safa G; Luce K; Darrieux L; Tisseau L; Ortonne N
    J Am Acad Dermatol; 2014 Oct; 71(4):e149-50. PubMed ID: 25219741
    [No Abstract]   [Full Text] [Related]  

  • 2. CD30-positive Cutaneous Pseudolymphoma Caused by Tocilizumab in a Patient with Rheumatoid Arthritis: Case Report and Literature Review.
    Inoue A; Sawada Y; Ohmori S; Omoto D; Haruyama S; Yoshioka M; Nishio D; Nakamura M
    Acta Derm Venereol; 2016 May; 96(4):570-1. PubMed ID: 26631390
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous pseudolymphoma caused by tumor necrosis factor-α inhibitors was not induced by ustekinumab.
    Imafuku S; Tatsukawa R; Ito K; Nakayama J
    J Dermatol; 2012 Dec; 39(12):1070. PubMed ID: 22698067
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab.
    Rongioletti F; Borenstein M; Kirsner R; Kerdel F
    J Dermatolog Treat; 2003 Dec; 14(4):222-5. PubMed ID: 14660268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous lymphoid hyperplasia related to squaric acid dibutyl ester.
    Millican EA; Conley JA; Sheinbein D
    J Am Acad Dermatol; 2011 Jul; 65(1):230-2. PubMed ID: 21679832
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cutaneous pseudolymphoma with two types of anti-TNFα: a class effect?].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2012 Oct; 139(10):695-6. PubMed ID: 23122389
    [No Abstract]   [Full Text] [Related]  

  • 7. Cutaneous B-cell Pseudolymphoma in a Psoriatic Patient Treated with Cyclosporine.
    Takahashi T; Hata M; Iwata H; Seishima M
    Acta Derm Venereol; 2016 Aug; 96(6):824-5. PubMed ID: 26928776
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of cyclosporine in the treatment of a case of infliximab-induced erythrodermic psoriasis.
    Bruzzese V; Pepe J
    Int J Immunopathol Pharmacol; 2009; 22(1):235-8. PubMed ID: 19309571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-related CD8+ cutaneous pseudolymphoma: efficacy of methotrexate.
    Ingen-Housz-Oro S; Sbidian E; Ortonne N; Penso-Assathiany D; Chambrin V; Bagot M; Bachelez H; Wolkenstein P; Chosidow O
    Dermatology; 2013; 226(1):15-8. PubMed ID: 23343593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psoriasis coexisting with subacute cutaneous lupus erythematosus.
    Kontochristopoulos GJ; Giannadaki M; Doulaveri G; Christofidou E; Zakopoulou N
    J Eur Acad Dermatol Venereol; 2004 May; 18(3):385-6. PubMed ID: 15096170
    [No Abstract]   [Full Text] [Related]  

  • 11. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
    Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
    Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous pseudolymphoma induced by adalimumab and reproduced by infliximab in a patient with arthropathic psoriasis.
    Imafuku S; Ito K; Nakayama J
    Br J Dermatol; 2012 Mar; 166(3):675-8. PubMed ID: 21910704
    [No Abstract]   [Full Text] [Related]  

  • 13. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
    Lewis TG; Tuchinda C; Lim HW; Wong HK
    J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy).
    Sánchez-Regaña M; Sola-Ortigosa J; Alsina-Gibert M; Vidal-Fernández M; Umbert-Millet P
    J Eur Acad Dermatol Venereol; 2011 May; 25(5):579-86. PubMed ID: 21198950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatomyositis associated with anti-tumor necrosis factor therapy in a patient with psoriasis.
    Dicaro D; Bowen C; Dalton SR
    J Am Acad Dermatol; 2014 Mar; 70(3):e64-5. PubMed ID: 24528921
    [No Abstract]   [Full Text] [Related]  

  • 17. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
    Kamili QU; Miner A; Hapa A; Menter A
    J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of cutaneous pseudolymphoma associated with silicone injection.
    Lee MW; Choi JH; Sung KJ; Moon KC; Koh JK
    Acta Derm Venereol; 2004; 84(4):312-3. PubMed ID: 15339080
    [No Abstract]   [Full Text] [Related]  

  • 19. Imiquimod 5%: a successful treatment for pseudolymphoma.
    Baumgartner-Nielsen J; Lorentzen H
    Acta Derm Venereol; 2014 Jul; 94(4):469. PubMed ID: 24213849
    [No Abstract]   [Full Text] [Related]  

  • 20. Tattoo ink-related cutaneous pseudolymphoma: a rare but significant complication. Case report and review of the literature.
    Marchesi A; Parodi PC; Brioschi M; Marchesi M; Bruni B; Cangi MG; Vaienti L
    Aesthetic Plast Surg; 2014 Apr; 38(2):471-8. PubMed ID: 24570180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.